Acumen price target lowered to $10 from $12 at BofA

BofA analyst Jason Zemansky lowered the firm’s price target on Acumen (ABOS) to $10 from $12 and keeps a Buy rating on the shares. The firm remains “encouraged” ahead of the key ALTITUDE-AD readout, which is on-track for late 2026 and given the sizeable opportunity in Alzheimer’s it continues to see a favorable risk/ reward for shares, the analyst tells investors following Acumen’s Q4 update.